کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2474622 1113152 2015 12 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Insoluble drug delivery strategies: review of recent advances and business prospects
ترجمه فارسی عنوان
استراتژی های تحویل نامطلوب دارو: بررسی پیشرفت های اخیر و چشم انداز های تجاری
کلمات کلیدی
قابلیت دسترسی بیولوژیک، کوکریستالها، انحلال پذیری، پیچیدگی شامل، نانوذرات، فرمولاسیون خودموسیقی، پرولپوزوم ها
موضوعات مرتبط
علوم پزشکی و سلامت داروسازی، سم شناسی و علوم دارویی اکتشاف دارویی
چکیده انگلیسی

The emerging trends in the combinatorial chemistry and drug design have led to the development of drug candidates with greater lipophilicity, high molecular weight and poor water solubility. Majority of the failures in new drug development have been attributed to poor water solubility of the drug. Issues associated with poor solubility can lead to low bioavailability resulting in suboptimal drug delivery. About 40% of drugs with market approval and nearly 90% of molecules in the discovery pipeline are poorly water-soluble. With the advent of various insoluble drug delivery technologies, the challenge to formulate poorly water soluble drugs could be achieved. Numerous drugs associated with poor solubility and low bioavailabilities have been formulated into successful drug products. Several marketed drugs were reformulated to improve efficacy, safety and patient compliance. In order to gain marketing exclusivity and patent protection for such products, revitalization of poorly soluble drugs using insoluble drug delivery technologies have been successfully adopted by many pharmaceutical companies. This review covers the recent advances in the field of insoluble drug delivery and business prospects.

The improved formulation of existing drugs is turning out to be lucrative business for pharmaceutical industry which is facing innovation deficit these days for new molecules. New dosage form, change of forms of drugs (ester/salt), prodrug/active metabolite of drug, different routes of administration are few changes that pharmaceutical companies are exploring for 505(b)(2) fillings. Significant number of insoluble drugs in the market provides profitable strategies for pharmaceutical companies to file NDA under 505(b)(2) with improved formulations providing faster dissolution and enhanced bioavailability. Hence this review summarizes various solubilization technologies. The recent advances, clinical benefits and business potentials of these technologies are discussed in detail.Figure optionsDownload as PowerPoint slide

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Acta Pharmaceutica Sinica B - Volume 5, Issue 5, September 2015, Pages 442–453
نویسندگان
, ,